Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)

Neuromuscular Blockade Clinical Trial

— NEAT-3  

Official title:

Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02241304
• Other study ID #: ADBV-ABS-0214-NEAT-3H
• Secondary ID: 028605/2014/OTIG
• Status: Completed
• Phase: N/A
• First received: July 8, 2014
• Last updated: January 27, 2016
• Start date: July 2014
• Est. completion date: December 2015

Study information

• Verified date: January 2016
• Source: University of Debrecen
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hungary: The Office for Health Authorization and Administrative Procedures
• Study type: Observational

Clinical Trial Summary

TetraGraph is a newly developed EMG-based, quantitative, battery-powered neuromuscular monitoring system intended for daily clinical use. The primary aim of this clinical investigation is to examine the applicability (ease of use, equipment need, etc.), repeatability (precision or internal consistency) and performance (signal quality, accuracy of outcome, voltage of stimulation output before and during a stimulus) of the Tetragraph device in patients undergoing elective surgeries requiring neuromuscular blockade.

Description:

The TetraGraph will be tested in 50 consenting patients undergiong elective surgeries requiring neuromuscular blockade. The left of right hand of the patients will be randomly studied. After the induction of anesthesia but before the administration of muscle relaxant train-of-four (TOF) stimulation will be started with 30 mA current intensity, 0.2 msec pulse duration at 20 sec intervals. The stimulation will be left to run until extubation. The TetraGraph device will be set not to show measurement results on the screen but save them on the SD card for later analysis. This way TetraGraph will not influence clinical decisions and patient care. During the operations we will record the number of muscle twitches in return to stimulation, the time and dose of muscle relaxant and opioid administration, the time of use of electrocautery and the skin temperature.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years or older.

2. American Society of Anesthesiology (ASA) physical status I-III criteria (Table I).

3. Subject has provided written informed consent.

Exclusion Criteria:

1. Presence of an underlying neuromuscular disease.

2. Presence of renal or hepatic disease.

3. Subject has open skin sores in the locations needed for electrode application (forearms).

4. Patient is taking anti-seizure medication

5. Patient is taking oral anti-cholinesterase (e.g., therapy for myasthenia gravis)

6. Magnesium sulfate administration is required

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Neuromuscular Blockade

Locations

Country	Name	City	State
Hungary	University of Debrecen	Debrecen

Sponsors (1)

Lead Sponsor	Collaborator
University of Debrecen

Country where clinical trial is conducted

Hungary, 

References & Publications (1)

1. Gätke MR, Viby-Mogensen J, Rosenstock C, Jensen FS, Skovgaard LT. Acta Anaesthesiol Scand 2002;46:207-13. 2. Berg H, Viby-Mogensen J, Roed J, Mortensen CR, Engbaek J, Skovgaard LT, Krintel JJ. Acta Anaesthesiol Scand 1997;41:1095-103. 3. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Anesth Analg 2008;107:130-7. 4. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS, Nisman M. Anesthesiology 2008;109:389-98. 5. Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Marymont JH, Vender JS, Gray J, Landry E, Gupta DK. Anesthesiology 2011;115:946-54. 6. Murphy GS, Brull SJ. Anesth Analg 2010;111:120-8. 7. Hemmerling TM, Le N. Can J Anesth 2007;54: 58-72. 8. Gätke MR, Viby-Mogensen J, Rosenstock C, Jensen FS, Skovgaard LT. Acta Anaesthesiol Scand 2002; 46: 207-13. 9. Brull SJ, Silverman DG. Anesth Analg 1993;77:352-5. 10. Grayling M, Sweeney BP. Anaesthesia 2007; 62:806-9. 11. Liang SS, Stewart PA, Phillips S. Anesth Analg 2013;117:373-9.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary performance assessment of TetraGraph device	The primary objective of this study is to provide safety & performance data of the TetraGraph device in anesthetized patients. Performance will be assessed post hoc by analyzing objective EMG data from the SD card and correlating the responses to annotations made during the surgical procedure (e.g., correlating the EMG responses to the time of NMBA or reversal agent administration). No clinical decisions will be made based on any objective measurements made by the TetraGraph. There are no specific timepoints concerning the primary outcome measure of the study.	participants will be followed for the duration of their hospital stay, an expected avarage of five days	No
Secondary	Secondary performance assessment of TetraGraph Device	The secondary outcome measures is a composite of several safety and performance data examined during the operations and the hospital stay: Acceptable levels of electrical noise when no stimulus is being applied; Ensuring that the stimulus artifact does not obscure the EMG response when a stimulus is applied; Appearance of an EMG response at threshold stimulation levels, just sufficient to elicit a palpable twitch response; Consistency of the EMG response amplitudes during repeated (ST and TOF) protocols (variability <10%); Consistency of EMG response characteristics independent of patient age, gender, or weight; Consistency of EMG response characteristics independent whether the right or left arm is stimulated; Skin reaction to stimulation or recording electrodes; Overall usability of the device for clinicians and operators; collecting recommendations for improving ease of use.	participants will be followed for the duration of the hospital stay, an expected avarage of 5 days	No
Secondary	Safety of TetraGraph device	The safety of Tetragraph device will be assesses by checking the stimulating and recording electrode positions for skin reactions.	participants will be followed for the duration of hospital stay, an expected avarage of 5 days	Yes